Targeting the p53 pathway in Ewing Sarcoma

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Neilsen, Paul M ^a   Pishas, Kathleen I ^a   Callen, David F ^a   Thomas, David M ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; MI 219; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; SOMATOMEDIN C RECEPTOR; TENOVIN 6; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG BINDING; DRUG MECHANISM; EWING SARCOMA; EXON; FIBROBLAST; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MASS SPECTROMETRY; MESENCHYMAL STEM CELL; MYXOSARCOMA; NONHUMAN; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; TUMOR SUPPRESSOR GENE;

EID: 79251576442     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/746939     Document Type: Review

References (139)

1. Lane D. P., p53, guardian of the genome Nature 1992 358 6381 15 16
2. Vousden K. H., Prives C., Blinded by the light: the growing complexity of p53 Cell 2009 137 3 413 431
3. Vogelstein B., Kinzler K. W., Cancer genes and the pathways they control Nature Medicine 2004 10 8 789 799
4. Vogelstein B., Lane D., Levine A. J., Surfing the p53 network Nature 2000 408 6810 307 310
5. Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer-Kuntshcik M., Gadner H., Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours Oncogene 1993 8 10 2683 2690
6. Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y., Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas Cancer Research 1993 53 21 5284 5288
7. Hamelin R., Zucman J., Melot T., Delatire O., Thomas G., p53 Mutations in human tumors with chimeric EWS/FLI-1 genes International Journal of Cancer 1994 57 3 336 340
8. Patio-Garca A., Sierrasesmaga L., Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients Cancer Genetics and Cytogenetics 1997 98 1 50 55
9. Radig K., Schneider-Stock R., Rse I., Mittler U., Oda Y., Roessner A., p53 and ras mutations in Ewing's sarcoma Pathology Research and Practice 1998 194 3 157 162
10. Tsuchiya T., Sekine K., Hinohara S., Namiki T., Nobori T., Kaneko Y., Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma Cancer Genetics and Cytogenetics 2000 120 2 91 98
11. López-Guerrero J. A., Pelln A., Noguera R., Carda C., Llombart-Bosch A., Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors Laboratory Investigation 2001 81 6 803 814
12. Huang H.-Y., Illei P. B., Zhao Z., Mazumdar M., Huvos A. G., Healey J. H., Wexler L. H., Gorlick R., Meyers P., Ladanyi M., Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse Journal of Clinical Oncology 2005 23 3 548 558
13. Park Y.-K., Chi S. G., Kim Y. W., Park H. R., Unni K. K., P53 mutations in Ewing's sarcoma Oncology Reports 2001 8 3 533 537
14. Schaefer K.-L., Eisenacher M., Braun Y., Brachwitz K., Wai D. H., Dirksen U., Lanvers-Kaminsky C., Juergens H., Herrero D., Stegmaier S., Koscielniak E., Eggert A., Nathrath M., Gosheger G., Schneider D. T., Bury C., Diallo-Danebrock R., Ottaviano L., Gabbert H. E., Poremba C., Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy European Journal of Cancer 2008 44 5 699 709
15. Iwamoto Y., Diagnosis and treatment of Ewing's sarcoma Japanese Journal of Clinical Oncology 2007 37 2 79 89
16. Riggi N., Stamenkovic I., The biology of Ewing sarcoma Cancer Letters 2007 254 1 1 10
17. Fletcher C. D. M., Gustafson P., Rydholm A., Willn H., kerman M., Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification Journal of Clinical Oncology 2001 19 12 3045 3050
18. Pilotti S., Della Torre G., Lavarino C., Di Palma S., Sozzi G., Minoletti F., Rao S., Pasquini G., Azzarelli A., Rilke F., Pierotti M. A., Distinct mdm2/p53 expression in patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms Journal of Pathology 1997 181 1 14 24
19. Dei Tos A. P., Doglioni C., Piccinin S., Maestro R., Mentzel T., Barbareschi M., Boiocchi M., Fletcher C. D. M., Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma Journal of Pathology 1997 181 1 8 13
20. Schneider-Stock R., Walter H., Rys J., Radig K., Hoang-Vu C., Roessner A., No correlation of c-myc overexpression and p53 mutations in liposarcomas Virchows Archiv 1998 433 4 315 321
21. Schneider-Stock R., Ziegeler A., Haeckel C., Franke D.-S., Rys J., Roessner A., Prognostic relevance of p53 alterations and Mib-1 proliferation index in subgroups of primary liposarcomas Clinical Cancer Research 1999 5 10 2830 2835
22. Barretina J., Taylor B. S., Banerji S., Ramos A. H., Lagos-Quintana M., Decarolis P. L., Shah K., Socci N. D., Weir B. A., Ho A., Chiang D. Y., Reva B., Mermel C. H., Getz G., Antipin Y., Beroukhim R., Major J. E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T. J., Cibulskis K., Onofrio R. C., Saito T., Shukla N., Lau C., Nelander S., Silver S. J., Sougnez C., Viale A., Winckler W., Maki R. G., Garraway L. A., Lash A., Greulich H., Root D. E., Sellers W. R., Schwartz G. K., Antonescu C. R., Lander E. S., Varmus H. E., Ladanyi M., Sander C., Meyerson M., Singer S., Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nature Genetics 2010 42 8 715 721
23. Oda Y., Yamamoto H., Takahira T., Kobayashi C., Kawaguchi K., Tateishi N., Nozuka Y., Tamiya S., Tanaka K., Matsuda S., Yokoyama R., Iwamoto Y., Tsuneyoshi M., Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis Journal of Pathology 2005 207 4 410 421
24. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R. L., Dayton S. H., Herrera G. E., Yamamuro T., Kotoura Y., Sasaki M. S., Little J. B., Weichselbaum R. R., Ishizaki K., Yandell D. W., Mutation spectrum of the p53 gene in bone and soft tissue sarcomas Cancer Research 1992 52 22 6194 6199
25. Latres E., Drobnjak M., Pollack D., Oliva M. R., Ramos M., Karpeh M., Woodruff J. M., Cordon-Cardo C., Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas American Journal of Pathology 1994 145 2 345 355
26. Castresana J. S., Rubio M.-P., Gomez L., Kreicbergs A., Zetterberg A., Barrios C., Detection of TP53 gene mutations in human sarcomas European Journal of Cancer A 1995 31 5 735 738
27. Nawa G., Miyoshi Y., Yoshikawa H., Ochi T., Nakamura Y., Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours British Journal of Cancer 1999 80 8 1185 1189
28. Das P., Kotilingam D., Korchin B., Liu J., Yu D., Lazar A. J., Pollock R. E., Lev D., High prevalence of p53 exon 4 mutations in soft tissue sarcoma Cancer 2007 109 11 2323 2333
29. Felix C. A., Kappel C. C., Mitsudomi T., Nau M. M., Tsokos M., Crouch G. D., Nisen P. D., Winick N. J., Helman L. J., Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma Cancer Research 1992 52 8 2243 2247
30. Kusafuka T., Fukuzawa M., Oue T., Komoto Y., Yoneda A., Okada A., Mutation analysis of p53 gene in childhood malignant solid tumors Journal of Pediatric Surgery 1997 32 8 1175 1180
31. Mora J., Dobrenis A. M., Bussel J. B., Aledo A., p53 mutation and MDM2 amplification frequency pediatric rhabdomyosarcoma tumors and cell lines Medical and Pediatric Oncology 2000 35 2 96 103
32. Takahashi Y., Oda Y., Kawaguchi K.-I., Tamiya S., Yamamoto H., Suita S., Tsuneyoshi M., Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma Modern Pathology 2004 17 6 660 669
33. Schneider-Stock R., Radig K., Oda Y., Mellin W., Rys J., Niezabitowski A., Roessner A., p53 gene mutations in soft-tissue sarcomascorrelations with p53 immunohistochemistry and DNA ploidy Journal of Cancer Research and Clinical Oncology 1997 123 4 211 218
34. Dei Tos A. P., Doglioni C., Muffato G., Synovial sarcoma exhibits deregulation of the G1-S cell cycle checkpoint and of the apoptotic pathway Modern Pathology 1999 12 10A
35. Schneider-Stock R., Onnasch D., Haeckel C., Mellin W., Franke D.-S., Roessner A., Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas Virchows Archiv 1999 435 4 407 412
36. Oda Y., Sakamoto A., Satio T., Kawauchi S., Iwamoto Y., Tsuneyoshi M., Molecular abnormalities of p53, MDM2, and H-ras synovial sarcoma Modern Pathology 2000 13 9 994 1004
37. Andreassen A., Oyjord T., Hovig E., Holm R., Florenes V. A., Nesland J. M., Myklebost O., Hoie J., Bruland O. S., Borresen A.-L., Fodstad O., p53 Abnormalities in different subtypes of human sarcomas Cancer Research 1993 53 3 468 471
38. Leach F. S., Tokino T., Meltzer P., Burrell M., Oliner J. D., Smith S., Hill D. E., Sidransky D., Kinzler K. W., Vogelstein B., p53 Mutation and MDM2 amplification in human soft tissue sarcomas Cancer Research 1993 53 10 2231 2234
39. Patterson H., Gill S., Fisher C., Law M. G., Jayatilake H., Fletcher C. D. M., Thomas M., Grimer R., Gusterson B. A., Cooper C. S., Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas British Journal of Cancer 1994 69 6 1052 1058
40. Miller C. W., Aslo A., Won A., Tan M., Lampkin B., Koeffler H. P., Alterations of the p53, Rb and MDM2 genes in osteosarcoma Journal of Cancer Research and Clinical Oncology 1996 122 9 559 565
41. Hall K. L., Teneriello M. G., Taylor R. R., Lemon S., Ebina M., Linnoila R. I., Norris J. H., Park R. C., Birrer M. J., Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas Gynecologic Oncology 1997 65 2 330 335
42. Zhai Y.-L., Nikaido T., Toki T., Shiozawa A., Orii A., Fujii S., Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus British Journal of Cancer 1999 80 10 1658 1664
43. Miyajima K., Tamiya S., Oda Y., Adachi T., Konomoto T., Toyoshiba H., Masuda K., Tsuneyoshi M., Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction Cancer Letters 2001 164 2 177 188
44. Gokgoz N., Wunder J. S., Mousses S., Eskandarian S., Bell R. S., Andrulis I. L., Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma Cancer 2001 92 8 2181 2189
45. Overholtzer M., Rao P. H., Favis R., Lu X.-Y., Elowitz M. B., Barany F., Ladanyi M., Gorlick R., Levine A. J., The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability Proceedings of the National Academy of Sciences of the United States of America 2003 100 20 11547 11552
46. Petitjean A., Achatz M. I. W., Borresen-Dale A. L., Hainaut P., Olivier M., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 2007 26 15 2157 2165
47. Lane D. P., p53 and human cancers British Medical Bulletin 1994 50 3 582 599
48. Lopez-Guerrero J. A., Machado I., Scotlandi K., Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. International Journal of Cancer. In press
49. Mulligan L. M., Matlashewski G. J., Scrable H. J., Cavenee W. K., Mechanisms of p53 loss in human sarcomas Proceedings of the National Academy of Sciences of the United States of America 1990 87 15 5863 5867
50. Miller C. W., Aslo A., Tsay C., Slamon D., Ishizaki K., Toguchida J., Yamamuro T., Lampkin B., Koeffler H. P., Frequency and structure of p53 rearrangements in human osteosarcoma Cancer Research 1990 50 24 7950 7954
51. Momand J., Jung D., Wilczynski S., Niland J., The MDM2 gene amplification database Nucleic Acids Research 1998 26 15 3453 3459
52. Wu X., Bayle J. H., Olson D., Levine A. J., The p53-mdm-2 autoregulatory feedback loop Genes and Development 1993 7 7 1126 1132
53. Haupt Y., Maya R., Kazaz A., Oren M., Mdm2 promotes the rapid degradation of p53 Nature 1997 387 6630 296 299
54. Kubbutat M. H. G., Jones S. N., Vousden K. H., Regulation of p53 stability by Mdm2 Nature 1997 387 6630 299 303
55. Pedeutour F., Forus A., Coindre J.-M., Berner J.-M., Nicolo G., Michiels J.-F., Terrier P., Ranchere-Vince D., Collin F., Myklebost O., Turc-Carel C., Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors Genes Chromosomes and Cancer 1999 24 1 30 41
56. Stott F. J., Bates S., James M. C., McConnell B. B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K. H., Peters G., The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2 The EMBO Journal 1998 17 17 5001 5014
57. Pomerantz J., Schreiber-Agus N., Ligeois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.-W., Cordon-Cardo C., DePinho R. A., The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 1998 92 6 713 723
58. Ladanyi M., Lewis R., Jhanwar S. C., Gerald W., Huvos A. G., Healey J. H., MDM2 and CDK4 gene amplification in Ewing's sarcoma Journal of Pathology 1995 175 2 211 217
59. Wei G., Antonescu C. R., De Alava E., Leung D., Huvos A. G., Meyers P. A., Healey J. H., Ladanyi M., Prognostic impact of INK4A deletion in Ewing sarcoma Cancer 2000 89 4 793 799
60. Brownhill S. C., Taylor C., Burchill S. A., Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT British Journal of Cancer 2007 96 12 1914 1923
61. Bartel F., Schulz J., Bhnke A., Blmke K., Kappler M., Bache M., Schmidt H., Wrl P., Taubert H., Hauptmann S., Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis International Journal of Cancer 2005 117 3 469 475
62. Danovi D., Meulmeester E., Pasini D., Migliorini D., Capra M., Frenk R., De Graaf P., Francoz S., Gasparini P., Gobbi A., Helin K., Pelicci P. G., Jochemsen A. G., Marine J.-C., Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity Molecular and Cellular Biology 2004 24 13 5835 5843
63. Shvarts A., Bazuine M., Dekker P., Ramos Y. F. M., Steegenga W. T., Merckx G., Van Ham R. C. A., Van Der Houven Van Oordt W., Van Der Eb A. J., Jochemsen A. G., Isolation and identification of the human homolog of a new p53-binding protein, Mdmx Genomics 1997 43 1 34 42
64. Laurie N. A., Donovan S. L., Shih C.-S., Zhang J., Mills N., Fuller C., Teunisse A., Lam S., Ramos Y., Mohan A., Johnson D., Wilson M., Rodriguez-Galindo C., Quarto M., Francoz S., Mendrysa S. M., Guy R. K., Marine J.-C., Jochemsen A. G., Dyer M. A., Inactivation of the p53 pathway in retinoblastoma Nature 2006 444 7115 61 66
65. Muller P. A.J., Caswell P. T., Doyle B., Iwanicki M. P., Tan E. H., Karim S., Lukashchuk N., Gillespie D. A., Ludwig R. L., Gosselin P., Cromer A., Brugge J. S., Sansom O. J., Norman J. C., Vousden K. H., Mutant p53 drives invasion by promoting integrin recycling Cell 2009 139 7 1327 1341
66. Kovar H., Pospisilova S., Jug G., Printz D., Gadner H., Response of Ewing tumor cells to forced and activated p53 expression Oncogene 2003 22 21 3193 3204
67. Ladanyi M., EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights Cancer Biology amp; Therapy 2002 1 4 330 336
68. Abudu A., Mangham D. C., Reynolds G. M., Pynsent P. B., Tillman R. M., Carter S. R., Grimer R. J., Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis British Journal of Cancer 1999 79 7-8 1185 1189
69. de Alava E., Antonescu C. R., Panizo A., Leung D., Meyers P. A., Huvos A. G., Pardo-Mindn F. J., Healey J. H., Ladanyi M., Prognostic impact of P53 status in Ewing sarcoma Cancer 2000 89 4 783 792
70. Ozaki T., Paulussen M., Poremba C., Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors Genes Chromosomes and Cancer 2001 32 2 164 171
71. Savola S., Klami A., Tripathi A., Niini T., Serra M., Picci P., Kaski S., Zambelli D., Scotlandi K., Knuutila S., Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors BMC Cancer 2009 9, article 17
72. Neilsen P. M., Cheney K. M., Li C.-W., Chen J. D., Cawrse J. E., Schulz R. B., Powelt J. A., Kumar R., Callen D. F., Identification of ANKRD11 as a p53 coactivator Journal of Cell Science 2008 121 21 3541 3552
73. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., Kovar H., Joubert I., De Jong P., Rouleau G., Aurias A., Thomas G., Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 1992 359 6391 162 165
74. Zucman J., Melot T., Desmaze C., Ghysdael J., Plougastel B., Peter M., Zucker J. M., Triche T. J., Sheer D., Turc-Carel C., Ambros P., Combaret V., Lenoir G., Aurias A., Thomas G., Delattre O., Combinatorial generation of variable fusion proteins in the Ewing family of tumours The EMBO Journal 1993 12 12 4481 4487
75. Kovar H., Aryee D. N. T., Jug G., Henckl C., Schemper M., Delattre O., Thomas G., Gadner H., EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro Cell Growth and Differentiation 1996 7 4 429 437
76. Ouchida M., Ohno T., Fujimura Y., Rao V. N., Reddy E. S. P., Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts Oncogene 1995 11 6 1049 1054
77. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y., EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells The Journal of Clinical Investigation 1997 99 2 239 247
78. Toretsky J. A., Connell Y., Neckers L., Bhat N. K., Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides Journal of Neuro-Oncology 1997 31 1-2 9 16
79. Ban J., Bennani-Baiti I. M., Kauer M., Schaefer K.-L., Poremba C., Jug G., Schwentner R., Smrzka O., Muehlbacher K., Aryee D. N. T., Kovar H., EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma Cancer Research 2008 68 17 7100 7109
80. Li Y., Tanaka K., Fan X., Nakatani F., Li X., Nakamura T., Takasaki M., Yamamoto S., Iwamoto Y., Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors Cancer Letters 2010 294 1 57 65
81. Sorensen P. H. B., Lessnick S. L., Lopez-Terrada D., Liu X. F., Triche T. J., Denny C. T., A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG Nature Genetics 1994 6 2 146 151
82. Jeon I.-S., Davis J. N., Braun B. S., Sublett J. E., Roussel M. F., Denny C. T., Shapiro D. N., A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1 Oncogene 1995 10 6 1229 1234
83. Kaneko Y., Yoshida K., Handa M., Toyoda Y., Nishihira H., Tanaka Y., Sasaki Y., Ishida S., Higashino F., Fujinaga K., Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy Genes Chromosomes and Cancer 1996 15 2 115 121
84. Peter M., Couturier J., Pacquement H., Michon J., Thomas G., Magdelenat H., Delattre O., A new member of the ETS family fused to EWS in Ewing tumors Oncogene 1997 14 10 1159 1164
85. Martini A., La Starza R., Janssen H., Bilhou-Nabera C., Corveleyn A., Somers R., Aventin A., Fo R., Hagemeijer A., Mecucci C., Marynen P., Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia Cancer Research 2002 62 19 5408 5412
86. Hallor K. H., Mertens F., Jin Y., Meis-Kindblom J. M., Kindblom L.-G., Behrendtz M., Kaln A., Mandahl N., Panagopoulos I., Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma Genes Chromosomes and Cancer 2005 44 1 97 102
87. Rossi S., Szuhai K., Ijszenga M., Tanke H. J., Zanatta L., Sciot R., Fletcher C. D. M., DeiTos A. P., Hogendoorn P. C. W., EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma Clinical Cancer Research 2007 13 24 7322 7328
88. Zucman J., Delattre O., Desmaze C., Epstein A. L., Stenman G., Speleman F., Fletchers C. D. M., Aurias A., Thomas G., EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts Nature Genetics 1993 4 4 341 345
89. Antonescu C. R., Nafa K., Segal N. H., Dal Cin P., Ladanyi M., EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation Clinical Cancer Research 2006 12 18 5356 5362
90. Ladanyi M., Gerald W., Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor Cancer Research 1994 54 11 2837 2840
91. Clark J., Benjamin H., Gill S., Sidhar S., Goodwin G., Crew J., Gusterson B. A., Shipley J., Cooper C. S., Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma Oncogene 1996 12 2 229 235
92. Orndal C., Carlen B., Akerman M., Willen H., Mandahl N., Heim S., Rydholm A., Mitelman F., Chromosomal abnormaity t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry Cytopathology 1991 2 5 261 270
93. Panagopoulos I., Hglund M., Mertens F., Mandahl N., Mitelman F., man P., Fusion of the EWS and CHOP genes in myxoid liposarcoma Oncogene 1996 12 3 489 494
94. Turc-Carel C., Dal Cin P., Limon J., Li F., Sandberg A. A., Translocation X;18 in synovial sarcoma Cancer Genetics and Cytogenetics 1986 23 1 93
95. D'Arcy P., Maruwge W., Ryan B. A., Brodin B., The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability Molecular Cancer Research 2008 6 1 127 138
96. Lessnick S. L., Dacwag C. S., Golub T. R., The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts Cancer Cell 2002 1 4 393 401
97. Deneen B., Denny C. T., Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation Oncogene 2001 20 46 6731 6741
98. Braig M., Schmitt C. A., Oncogene-induced senescence: putting the brakes on tumor development Cancer Research 2006 66 6 2881 2884
99. Sala A., Casella I., Grasso L., Bellon T., Reed J. C., Miyashita T., Peschle C., Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53 Cancer Research 1996 56 9 1991 1996
100. Kauer M., Ban J., Kofler R., Walker B., Davis S., Meltzer P., Kovar H., A molecular function map of Ewing's sarcoma PLoS ONE 2009 4 4
101. Castillero-Trejo Y., Eliazer S., Xiang L., Richardson J. A., Ilaria R. L. Jr. , Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors Cancer Research 2005 65 19 8698 8705
102. Riggi N., Cironi L., Provero P., Suv M.-L., Kaloulis K., Garcia-Echeverria C., Hoffmann F., Trumpp A., Stamenkovic I., Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells Cancer Research 2005 65 24 11459 11468
103. Riggi N., Suv M.-L., Suv D., Cironi L., Provero P., Tercier S., Joseph J.-M., Stehle J.-C., Baumer K., Kindler V., Stamenkovic I., EWS-FLI-1 expression triggers a ewing's sarcoma initiation program in primary human mesenchymal stem cells Cancer Research 2008 68 7 2176 2185
104. Lin P. P., Pandey M. K., Jin F., Xiong S., Deavers M., Parant J. M., Lozano G., EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model Cancer Research 2008 68 21 8968 8975
105. Baserga R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research 1995 55 2 249 252
106. Baserga R., Resnicoff M., Dews M., The IGF-I receptor and cancer Endocrine 1997 7 1 99 102
107. Werner H., Roith D. L., The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis Critical Reviews in Oncogenesis 1997 8 1 71 92
108. Prieur A., Tirode F., Cohen P., Delattre O., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3 Molecular and Cellular Biology 2004 24 16 7275 7283
109. Thomas D. M., Wagner A. J., Specific targets in sarcoma and developmental therapeutics JNCCN Journal of the National Comprehensive Cancer Network 2010 8 6 677 685
110. Tolcher A. W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C. -C., Rodon J., Murphy B., Roth B., McCaffery I., Gorski K. S., Kaiser B., Zhu M., Deng H., Friberg G., Puzanov I., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 Journal of Clinical Oncology 2009 27 34 5800 5807
111. Olmos D., Postel-Vinay S., Molife L. R., Okuno S. H., Schuetze S. M., Paccagnella M. L., Batzel G. N., Yin D., Pritchard-Jones K., Judson I., Worden F. P., Gualberto A., Scurr M., de Bono J. S., Haluska P., Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study The Lancet Oncology 2010 11 2 129 135
112. Werner H., Karnieli E., Rauscher F. J. III, LeRoith D., Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene Proceedings of the National Academy of Sciences of the United States of America 1996 93 16 8318 8323
113. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., Kley N., Induction of the growth inhibitor IGF-binding protein 3 by p53 Nature 1995 377 6550 646 649
114. Froment P., Dupont J., Christophe-Marine J., Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival Cell Cycle 2008 7 19 3098 3103
115. Girnita L., Girnita A., Larsson O., Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8247 8252
116. Xiong L., Kou F., Yang Y., Wu J., A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop Journal of Cell Biology 2007 178 6 995 1007
117. Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E. A., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004 303 5659 844 848
118. Mller C. R., Paulsen E. B., Noordhuis P., Pedeutour F., Ster G., Myklebost O., Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A International Journal of Cancer 2007 121 1 199 205
119. Miyachi M., Kakazu N., Yagyu S., Katsumi Y., Tsubai-Shimizu S., Kikuchi K., Tsuchiya K., Iehara T., Hosoi H., Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells Clinical Cancer Research 2009 15 12 4077 4084
120. D'Arcy P., Ryan B. A., Brodin B., Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction Cancer Letters 2009 275 2 285 292
121. Van Maerken T., Speleman F., Vermeulen J., Lambertz I., De Clercq S., De Smet E., Yigit N., Coppens V., Philipp J., De Paepe A., Marine J.-C., Vandesompele J., Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma Cancer Research 2006 66 19 9646 9655
122. Coll-Mulet L., Iglesias-Serret D., Santidrin A. F., Cosialls A. M., De Frias M., Castao E., Camps C., Barragn M., De Sevilla A. F., Domingo A., Vassilev L. T., Pons G., Gil J., MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells Blood 2006 107 10 4109 4114
123. Gu L., Zhu N., Findley H. W., Zhou M., MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 Leukemia 2008 22 4 730 739
124. Kojima K., Konopleva M., Samudio I. J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L. T., Andreeff M., MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy Blood 2005 106 9 3150 3159
125. Pishas K. I., Al-Ejeh F., Zinonos I., Nutlin-3a is a potential therapeutic for Ewing Sarcoma. Clinical Cancer Research. In press
126. Rosen G., Wollner N., Tan C., Disease free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four drug sequential chemotherapy Cancer 1974 33 2 384 393
127. Grier H. E., Krailo M. D., Tarbell N. J., Link M. P., Fryer C. J. H., Pritchard D. J., Gebhardt M. C., Dickman P. S., Perlman E. J., Meyers P. A., Donaldson S. S., Moore S., Rausen A. R., Vietti T. J., Miser J. S., Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone New England Journal of Medicine 2003 348 8 694 701
128. Shangary S., Qin D., McEachern D., Liu M., Miller R. S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., Bernard D., Zhang J., Lu Y., Gu Q., Shah R. B., Pienta K. J., Ling X., Kang S., Guo M., Sun Y., Yang D., Wang S., Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proceedings of the National Academy of Sciences of the United States of America 2008 105 10 3933 3938
129. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L. G. G. C., Masucci M., Pramanik A., Selivanova G., Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nature Medicine 2004 10 12 1321 1328
130. Lain S., Hollick J. J., Campbell J., Staples O. D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K. E., Baker L., Thompson A., Mathers J., Holland S. J., Stark M. J. R., Pass G., Woods J., Lane D. P., Westwood N. J., Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008 13 5 454 463
131. Langley E., Pearson M., Faretta M., Bauer U.-M., Frye R. A., Minucci S., Pelicci P. G., Kouzarides T., Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence The EMBO Journal 2002 21 10 2383 2396
132. Vaquero A., Scher M. B., Dong H. L., Sutton A., Cheng H.-L., Alt F. W., Serrano L., Sternglanz R., Reinberg D., SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis Genes and Development 2006 20 10 1256 1261
133. Vaziri H., Dessain S. K., Eaton E. N., Imai S.-I., Frye R. A., Pandita T. K., Guarente L., Weinberg R. A., hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase Cell 2001 107 2 149 159
134. Tang Y., Luo J., Zhang W., Gu W., TTip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis Molecular Cell 2006 24 6 827 839
135. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W., Acetylation is indispensable for p53 activation Cell 2008 133 4 612 626
136. Choong M. L., Yang H., Lee M. A., Lane D. P., Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy Cell Cycle 2009 8 17 2810 2818
137. Sobell H. M., Actinomycin and DNA transcription Proceedings of the National Academy of Sciences of the United States of America 1985 82 5328 5331
138. Veal G. J., Cole M., Errington J., Parry A., Hale J., Pearson A. D.J., Howe K., Chisholm J. C., Beane C., Brennan B., Waters F., Glaser A., Hemsworth S., McDowell H., Wright Y., Pritchard-Jones K., Pinkerton R., Jenner G., Nicholson J., Elsworth A. M., Boddy A. V., Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group study Clinical Cancer Research 2005 11 16 5893 5899
139. Mondick J. T., Gibiansky L., Gastonguay M. R., Skolnik J. M., Cole M., Veal G. J., Boddy A. V., Adamson P. C., Barrett J. S., Population pharmacokinetic investigation of actinomycin-D in children and young adults Journal of Clinical Pharmacology 2008 48 1 35 42